Monoclonal Antibodies for the Treatment of Ocular Diseases

Area of Science:

• Ophthalmology
• Immunology
• Biotechnology

Background:

• Monoclonal antibodies (mAbs) are biologic agents that have transformed cancer therapy through targeted mechanisms like ADCC and CDC.
• Initially developed for oncology, mAbs are now increasingly utilized for treating various ocular diseases.
• Technological advancements have enabled the development of diverse mAb types, including chimeric, humanized, and fully human antibodies.

Purpose of the Study:

• To review the current applications of monoclonal antibodies (mAbs) in treating ocular diseases.
• To discuss the specificity and diverse therapeutic mechanisms of mAbs in ophthalmology.
• To highlight the benefits, drawbacks, effectiveness, and risks of using mAbs for prevalent eye conditions.

Main Methods:

• Review of current literature on monoclonal antibody applications in ophthalmology.
• Analysis of mAb mechanisms, including antigen binding, immune system engagement, and direct cancer cell interference.
• Focus on specific ocular diseases such as age-related macular disease, diabetic retinopathy, and uveitis.

Main Results:

• Monoclonal antibodies demonstrate significant therapeutic potential in treating various ocular diseases.
• Humanized mAbs are currently used for conditions like age-related macular disease, diabetic retinopathy, and uveitis.
• Ongoing research explores new applications for mAbs, including in viral ocular infections like SARS-CoV-2.

Conclusions:

• Monoclonal antibodies represent a significant advancement in ocular disease treatment, offering targeted and effective therapeutic options.
• The review underscores the importance of understanding mAb mechanisms, benefits, and risks for optimal patient outcomes in ophthalmology.
• Continued innovation in mAb technology promises further expansion of their applications in managing complex eye conditions and emerging diseases.